Dalpiciclib Plus Pyrotinib May Be a Potential Chemo-Free Treatment Option in HER2-Positive Advanced Breast Cancer

Article

An interim analysis indicated that dalpiciclib plus pyrotinib yielded promising results in patients with HER2-positive advanced stage breast cancer.

Dalpiciclib (SHR6390) combined with pyrotinib (Irene) showed promising efficacy and could be a potential oral, chemotherapy-free regimen for patients with HER2-positive advanced breast cancer, according to preliminary findings from a single-arm phase 2 prospective study (NCT04293276).

Findings from the interim analysis indicated that a total of 28 patients experienced an objective response, translating to an objective response rate (ORR) of 70%, meeting the primary end point of the analysis. Additionally, 2.5% (n = 1) of patients treated with the combination achieved a complete response and 67.5% (n = 27) of patients achieved a partial response. During the follow-up of 7.4 months, 12 progression-free survival (PFS) events occurred; the median PFS has not yet been reached.

“[Patients with[ HER2-positive advanced breast cancer who had not received more than 1 line of systemic therapy in advanced setting were recruited. Prior CDK4/6 inhibitors and HER2 targeted [tyrosine kinase inhibitors] were not allowed,” Min Yan, MD, a medical oncologist at Sutter Health, said during a presentation on the findings at the 2021 European Society of Medical Oncology Congress.

At data cutoff, 41 patients were enrolled, 40 of whom were eligible for efficacy, with 1 having withdrawn prior to the efficacy assessment. Patients had a median age of 53 years, and 90.2% (n = 37) had an ECOG performance status of 1. Additionally, 43.9% (n = 18) were hormone receptor (HR)– positive. At the time of screening, 92.7% (n = 38) had visceral metastases, 53.7% (n = 22) had lung metastases, 41.5% had liver metastases, and 34.1% had brain metastases. Moreover, 58.5% (n = 24) of patients had 3 or more metastatic sites.

A total of 51.2% (n = 21) of patients received 1 previous line of therapy and 48.8% (n = 28) had 0 lines of prior therapy. Additionally, 68.3% (n = 28) had previously received trastuzumab (Herceptin), and 31.7% (n = 13) were trastuzumab-naïve. Moreover, 87.8% (n = 36) were not resistant to trastuzumab. Investigators also reported that 92.7% (n = 38) had received prior chemotherapy, and 29,3% (n = 12) had received prior endocrine therapy.

Patients received 125 mg of dalpiciclib daily for 3 weeks, with 1 week off, and 400 mg of pyrotinib daily during the 28-day cycles.

Enrollment on stage 2 of the study was dependent on whether 13 or more of 23 evaluable patients in stage 1 were responders.

In a subgroup analysis, patients who were HR-positive had an ORR of 55.6% (n = 10). Additionally, patients who had no prior lines of therapy had an ORR of 75.0% (n = 15) compared with 65.0% (n = 13) among those who had 1 prior line of therapy. Investigators also reported that patients who were trastuzumab resistant had an ORR of 80.0% (n = 4) compared with 76.9% (n = 10) among those who were trastuzumab-naïve and 66.7% (n = 18) among those who were treated with trastuzumab. Additionally, an ORR was reported in 84.6% (n = 11) of patients who had brain metastases vs 70.3% (n = 26) in those who with visceral metastases and 66.7% (n = 2) in those who did not have visceral metastases.

All patients experienced some form of treatment-related adverse effects (TRAEs); however, most TRAEs were tolerable. A total of 22.0% (n = 9) of patients required dose reductions, although no treatment discontinuations due to AEs were reported.

A total of 75.6% (n = 31) of patients had grade 3/4 AEs. The most common grade 3/4 AEs were neutropenia (58.5%; n = 24), leukopenia (56.1%; n = 23), and diarrhea (17.1%; n = 7).

Reference

Yan M, Niu L, Zhang M, et al. Dalpiciclib, a novel CDK4/6 inhibitor, combined with pyrotinib for HER2+ advanced breast cancer: interim results of a phase II trial. Poster presented at the 2021 European Society of Medical Oncology Congress. September 16-21, 2021. Virtual. Accessed October 5, 2021. Abstract 276P.

Related Videos
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
Rani Bansal, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
Related Content